author-photo

Ander Urruticoechea

The Royal Marsden NHS Foundation Trust

77

Papers

2375

Citations

Citation Trend

Filter By

Papers (57) Sort By

Journal Conference Others

Discovery and Proof-of-Concept Study of Nuclease Activity as a Novel Biomarker for Breast Cancer Tumors.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (3)
Abstract PS5-39: Tumour cellularity size as a biomarker to predict response afterneoadjuvant endocrine therapy: Correlation analysis between Ki67 expression and PEPI score

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

2019 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (19)
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

2019 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (19)
Abstract CT219: Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score®(RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial)

2019 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (2)
Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD)

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

2019 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (4)
THU0186 Rheumatoid arthritis and interstitial lung disease. multicentric retrospective study of 118 patients treated with biological no anti tnf

2018 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (14)